Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Theranos changed health-tech regulation by exposing a gap between two oversight systems: CLIA could certify a laboratory’s operations while the Food and Drug Administration (FDA) often exercised enforcement discretion over laboratory-developed tests (LDTs). A company could therefore put patient-facing assays into use as a laboratory service without going through the premarket device review normally applied to an in-vitro diagnostic (IVD) sold as a medical device. Theranos combined that gap with trade secrecy and aggressive investor claims. The result was inaccurate patient results, invalidated testing, criminal convictions and a regulatory push toward judging a test by its risk, intended use and scale rather than solely by where it is performed.
What Theranos exposed about the old oversight model
Theranos opened a CLIA-certified laboratory in Newark, California, in 2012. It claimed that proprietary microfluidics could run many tests from a finger-prick sample. Later evidence showed that the company diluted samples and used modified conventional analyzers for important testing instead of relying solely on its claimed technology. Because Theranos presented the service as an LDT laboratory operation, its tests were not subject to FDA premarket review for roughly two years, according to the Pew Charitable Trusts.
That status did not mean the laboratory was outside all regulation. CLIA requirements covered laboratory personnel, procedures, records, quality control and proficiency testing. But CLIA laboratory certification is not the same as FDA review of a diagnostic product’s design, intended use, analytical performance and clinical claims. The distinction allowed a high-profile startup to reach patients while keeping the underlying technology and validation work secret.
FDA inspections in August and September 2015 found violations involving proprietary collection tubes and laboratory records. The Centers for Medicare & Medicaid Services (CMS) warned the laboratory, revoked its certificate and invalidated patient results. The Department of Justice later reported inaccurate prostate-specific antigen (PSA), human chorionic gonadotropin (HCG) and blood-thinner-related results. Theranos eventually concluded that every analyzer test had affected patients and voided all analyzer tests.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
The scandal demonstrated that laboratory certification alone cannot answer the questions that matter for a widely distributed diagnostic: Does the assay measure the target reliably? Does the result support the medical decision being claimed? Is the system controlled when instruments, software, reagents or collection materials change? Who is notified when a result may be wrong?
The loophole: CLIA laboratory status versus FDA device review
The LDT framework developed when tests were designed, manufactured and used within a single laboratory. FDA historically exercised enforcement discretion over many such tests, while CMS administered CLIA. As technology companies began distributing software, instruments and test services across large networks, the original assumptions became harder to defend.
| Question | FDA device oversight | CMS/CLIA laboratory oversight |
|---|---|---|
| Primary focus | Safety and effectiveness of an IVD as a medical device, including intended use and risk | Quality of laboratory operations, personnel, procedures, records and proficiency |
| Premarket review | May require clearance, approval or another FDA pathway before marketing, depending on risk and product claims | Laboratory certification does not itself provide FDA marketing authorization for a device |
| Post-market tools | Adverse-event reporting, recalls, labeling controls, inspections and enforcement | Inspections, corrective action, sanctions, proficiency testing and certificate consequences |
| Typical historical LDT position | Enforcement discretion for many tests developed and used within a laboratory | Oversight applied to the laboratory performing the test |
| What Theranos added | A commercial, secretive system used at scale before ordinary device review | A laboratory certificate that did not reveal whether the proprietary system worked as claimed |
The loophole was therefore not a single exemption that made every LDT lawful. It was a mismatch between the place a test was performed and the risks created by its design, claims and distribution. Calling a commercial system an LDT did not remove other obligations, including truthful labeling, reliable records, patient protection and securities laws.
How the scandal unfolded and why it mattered to investors
2012: a certified laboratory opens
Theranos opened its Newark CLIA-certified laboratory in 2012. The certification helped present the company as a functioning clinical laboratory, even though certification did not validate every proprietary assay or authorize unsupported medical claims.
Recommended Free Tools
Late 2013 through 2015: claims about FDA status and revenue
The Securities and Exchange Commission’s 2018 complaint says Elizabeth Holmes told investors that FDA approval was unnecessary and that any application was voluntary, despite FDA representatives telling her that clearance or approval was necessary. The complaint describes the company’s characterization of FDA review as a voluntary “gold standard.” It also says Theranos projected more than $100 million in 2014 revenue and approximately $1 billion in 2015 revenue, while describing those projections as unsupported. The Department of Justice reported that Theranos had raised more than $730 million by March 2015.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Those statements show why regulatory classification is also a securities-fraud issue. A pitch deck that turns an unresolved FDA question into a settled fact can mislead investors about launch timing, costs, customer access and liability. Projections must be identified as projections and tied to contracts, validated capacity or other independently checkable evidence.
2015: inspections and sanctions
FDA inspections in August and September 2015 identified problems with proprietary collection tubes and laboratory records. CMS subsequently warned the laboratory, revoked its CLIA certificate and invalidated patient results. The episode made clear that a laboratory can lose its operating authority even when a company has argued that its tests are outside FDA premarket review.
2022: criminal findings
The Justice Department reported patient exposure to inaccurate PSA, HCG and blood-thinner-related results. Theranos voided all analyzer tests after concluding that every analyzer test had patient impact. Holmes was convicted on investor-fraud counts and sentenced to 135 months, or 11 years and three months, in federal prison. Those criminal findings are distinct from allegations in the SEC complaint, although together they illustrate the consequences of unsupported technical and regulatory representations.
What FDA changed in 2024—and what changed again in 2025
On April 29, 2024, FDA announced a final rule making explicit that IVD products are devices under the Federal Food, Drug, and Cosmetic Act even when a laboratory manufactures them. The rule announced a four-year phaseout of general enforcement discretion for LDTs. FDA described a future in which affected tests would face requirements such as premarket review, quality-system controls, adverse-event reporting, establishment registration and device listing, controlled labeling and investigational-use requirements.
FDA Commissioner Robert M. Califf said the agency could not stand by while Americans relied on test results without assurance that the tests worked. The policy goal was equal treatment for laboratory- and non-laboratory-manufactured IVDs when their risks and uses were comparable.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
The legal status is not the same as the 2024 announcement. A federal district court vacated the May 6, 2024 final rule on March 31, 2025. FDA then issued a final rule on September 19, 2025, reverting the regulation text to its pre-2024 wording. The broad policy debate remains unresolved. Therefore, a startup or investor should not describe the 2024 phaseout as currently operative; it was an announced framework whose legal effect was removed by the vacatur and subsequent reversion.
Why a risk-based approach gained momentum
Theranos did not create the LDT debate. FDA and stakeholders had discussed LDT oversight for years. The scandal supplied a vivid example of why the debate could no longer be framed only as laboratory versus device. A finger-prick test used in one local hospital presents a different distribution and failure profile from a branded system deployed through retail sites, pharmacies or a national health network.
Free tools Windows power users keep installed
One-click scans. No signup required.
| Regulatory question | Lower-risk, limited setting | Higher-risk, broad deployment |
|---|---|---|
| Distribution | Low-volume testing within one laboratory with direct professional oversight | National or multi-site service with results flowing to many clinicians and patients |
| Technology | Established instruments and methods with controlled local procedures | Novel instruments, collection devices, software or algorithms requiring system-level validation |
| Claims | Narrow, clearly defined use supported by local evidence | Claims that influence diagnosis, treatment, medication dosing or population screening |
| Controls | Routine laboratory quality controls and documented supervision | Formal design controls, change control, complaint handling, adverse-event reporting and traceability |
| Evidence timing | Continuous local verification may be appropriate for a limited method | Independent premarket evidence is more important before a product reaches a large population |
This comparison does not assign a legal category by itself. It shows why regulators increasingly look at intended use, patient harm, scale, instrumentation and software rather than accepting a label such as “LDT” without examining what the company actually sells and how it is used.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What a health-tech startup should prove before selling a diagnostic
1. Analytical validity
Document that the assay measures the target reliably. The validation file should cover accuracy or agreement with an appropriate comparator, precision, reportable range, analytical sensitivity, specificity, interference, carryover, specimen stability and failure rates where relevant. Test the complete workflow, including collection tubes, transport, preparation, instruments, reagents and software. A finger-prick claim is not validated merely because a conventional analyzer can produce a number after a sample is diluted.
2. Clinical validity
Show that the result supports the claimed medical use. Clinical validity connects an analytical signal to a disease, condition, risk or treatment decision in the population named on the label. A technically repeatable measurement can still be clinically misleading if the reference population, cutoff, prevalence or intended decision is wrong. Keep analytical validity and clinical validity as separate evidence packages and explain how each supports the marketing claim.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
3. Honest product classification
Map the product before launch. Consider intended use, risk, distribution scale, specimen type, instrumentation, algorithms, software updates and whether the company is selling a device, a laboratory service or both. Obtain written regulatory advice when the boundary is uncertain. Do not use LDT terminology as a substitute for analyzing FDA obligations, state requirements, CLIA duties or other applicable rules.
4. A quality system that survives change
Build documented design and manufacturing controls proportionate to risk. Maintain versioned specifications, calibration records, reagent and lot traceability, environmental controls, deviation investigations, corrective and preventive actions, complaint handling, proficiency testing and change-control approvals. The board should be able to see unresolved quality issues, not just a polished launch dashboard.
5. Patient and post-market safeguards
Define how the company will detect and report adverse events, investigate complaints, correct reports and notify clinicians or patients when a result may be unreliable. Establish a process for suspending a test or invalidating a result set. A plan that begins only after an inspection is too late; Theranos’s eventual decision to void analyzer tests shows the scale of remediation when traceability is inadequate.
6. Auditable commercial claims
Every investor, customer and partner statement should have an evidence owner. Revenue forecasts need contracts, capacity assumptions and a stated time period. Claims about military, pharmaceutical, clinical or regulatory relationships should be supported by signed agreements or independently verifiable records. Label projections as projections. Never present a voluntary regulatory filing as proof that approval is unnecessary, and never imply that a partner has endorsed performance without permission and documentation.
7. Independent technical review
Before a major financing or national rollout, commission review by people who were not responsible for building the assay. Give reviewers raw validation data, failed runs, excluded specimens, software versions and complaint records. A review limited to selected success cases cannot establish reproducibility.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
8. Protected dissent and escalation
Create a confidential route for scientists, laboratory staff and engineers to report data manipulation, protocol deviations, unsafe shortcuts or misleading claims. Carreyrou’s account of Theranos, based on extensive reporting and interviews with former employees and whistleblowers, illustrates why dissent must reach an independent compliance function or board committee. Retaliation risk suppresses exactly the information a quality system needs.
How investors and boards can use regulation as a financing milestone
Regulatory readiness should be a condition of scale, not a promise made after the financing closes. Before approving a large commercial commitment, require an independent technical review, reproducible validation data, verified partner claims, a documented classification analysis and a quality system that can produce records during an inspection. Ask which tests are actually running on which instruments, how often results are repeated, what percentage is invalid, and who can stop reporting.
Boards should also separate three questions that are often collapsed into one: whether the laboratory is certified, whether the test is analytically and clinically valid, and whether the company has the legal authority to market the product for its stated use. A “yes” to one does not answer the others.
What remains unresolved
The 2025 vacatur and FDA’s September 19, 2025 reversion mean that the precise federal LDT framework can change again. Startups should monitor current FDA, CMS and state requirements rather than rely on summaries of the 2024 rule. The durable lesson from Theranos is broader than any single rule: secrecy, a laboratory certificate and optimistic projections cannot substitute for validated performance, truthful claims, traceable records and a credible path to oversight.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsQuick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Say something about this film